Cassava Sciences, Inc.

NasdaqCM:SAVA 주식 보고서

시가총액: US$582.4m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Cassava Sciences 관리

관리 기준 확인 2/4

Cassava Sciences' CEO는 Remi Barbier, May1998 에 임명되었습니다 의 임기는 26.08 년입니다. 총 연간 보상은 $ 6.26M, 19% 로 구성됩니다. 19% 급여 및 81% 보너스(회사 주식 및 옵션 포함). 는 $ 26.11M 가치에 해당하는 회사 주식의 2.79% 직접 소유합니다. 26.11M. 경영진과 이사회의 평균 재임 기간은 각각 3.8 년과 13.1 년입니다.

주요 정보

Remi Barbier

최고 경영자

US$6.3m

총 보상

CEO 급여 비율19.0%
CEO 임기26.2yrs
CEO 소유권2.8%
경영진 평균 재임 기간3.9yrs
이사회 평균 재임 기간13.2yrs

최근 관리 업데이트

Recent updates

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Oct 17
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Jul 04
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate

Mar 05
We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Nov 19
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Cassava Sciences begins extension study of Alzheimer's drug simufilam

Oct 13

Cassava Sciences Stock: Huge Returns Or Catastrophic Losses

Sep 29

Cassava Sciences: Trying To Manage Expectations

Sep 21

Cassava Sciences reaches over five-month high on rising volumes

Sep 09

Cassava Sciences Looks As Good Of A Purchase As Ever

Sep 03

Cassava Sciences stock jumps 10% after director buys $860K shares

Aug 26

Cassava Sciences rally continues as stock up 39%

Aug 17

Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results

Aug 11

Cassava Sciences GAAP EPS of -$0.48 misses by $0.06

Aug 03

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Aug 03
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug

Jul 27

Cassava Sciences And Alzheimer's Disease: A Precipitious Path

Jun 10

Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate

May 31

Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait

Apr 19
Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait

3 Key Points To Remember About Cassava Sciences

Apr 07

Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences

Mar 31

Cassava Sciences: Why The Stock Is Rangebound

Feb 28

The FDA Deals Another Blow To Cassava Sciences' Bears

Feb 11

Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity

Feb 02

INmune Bio, The Biotech In My Stable For After Cassava Sciences

Jan 17

Cassava Sciences, Inc. - The Short Squeeze Has Started

Jan 06

Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam

Dec 30

Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth

Dec 28
Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth

Cassava Sciences Stock: Here We Go Again

Dec 21

Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing

Dec 02

Cassava Sciences Gets Underway Putting Simufilam To The Test

Nov 24

Cassava Sciences: Data Rules!

Nov 17

Cassava Sciences' Hypothesis Raises Doubts

Nov 08

Cassava Sciences Stock: Massive Potential Marred By Controversy

Nov 01

Cassava Sciences: Welcome To The Casino

Oct 25

Has Cassava Sciences Put Out The Fire For Now?

Sep 28

Cassava Sciences: Medical History In The Making

Sep 21

Cassava Sciences: One Doubtful Drug For One Doubtful Indication

Sep 15

We Think Cassava Sciences (NASDAQ:SAVA) Can Afford To Drive Business Growth

Sep 14
We Think Cassava Sciences (NASDAQ:SAVA) Can Afford To Drive Business Growth

More On Cassava Sciences' Controversy

Sep 04

Cassava Sciences Likely To Survive Latest Attack On Alzheimer's Drug, But Caveat Emptor

Aug 26

CEO 보상 분석

Remi Barbier 의 보수는 Cassava Sciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$48m

Dec 31 2023US$6mUS$1m

-US$97m

Sep 30 2023n/an/a

-US$95m

Jun 30 2023n/an/a

-US$90m

Mar 31 2023n/an/a

-US$83m

Dec 31 2022US$1mUS$1m

-US$76m

Sep 30 2022n/an/a

-US$71m

Jun 30 2022n/an/a

-US$61m

Mar 31 2022n/an/a

-US$46m

Dec 31 2021US$2mUS$975k

-US$32m

Sep 30 2021n/an/a

-US$21m

Jun 30 2021n/an/a

-US$13m

Mar 31 2021n/an/a

-US$9m

Dec 31 2020US$936kUS$920k

-US$6m

Sep 30 2020n/an/a

-US$5m

Jun 30 2020n/an/a

-US$4m

Mar 31 2020n/an/a

-US$4m

Dec 31 2019US$1mUS$899k

-US$5m

Sep 30 2019n/an/a

-US$4m

Jun 30 2019n/an/a

-US$4m

Mar 31 2019n/an/a

-US$6m

Dec 31 2018US$934kUS$875k

-US$7m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$10m

Mar 31 2018n/an/a

-US$11m

Dec 31 2017US$2mUS$875k

-US$12m

보상 대 시장: Remi 의 총 보상 ($USD 6.26M )은 US 시장( $USD 3.43M ).

보상과 수익: 회사가 수익성이 없는 동안 Remi 의 보상이 증가했습니다.

CEO

Remi Barbier (64 yo)

26.2yrs

테뉴어

US$6,263,038

보상

Mr. Remi Barbier founded Cassava Sciences, Inc. (formerly known as Pain Therapeutics, Inc.). since May 1998 and has been its President and Chief Executive Officer since May 1998 and served as its Principal...

리더십 팀

이름위치테뉴어보상소유권
Remi Barbier
Founder26.2yrsUS$6.26m2.79%
$ 16.2m
Eric Schoen
Chief Financial Officer5.8yrsUS$2.99m0.049%
$ 282.9k
R. Cook
Senior VP1.8yrsUS$1.27m0%
$ 0
James Kupiec
Chief Medical Officer3.5yrsUS$2.97m0.0083%
$ 48.6k
George Thornton
Senior Vice President of Technologyno data데이터 없음데이터 없음
Michael Zamloot
Senior Vice President of Technical Operationsno data데이터 없음데이터 없음
Michael Marsman
Senior Vice President of Regulatory Affairs1.7yrs데이터 없음데이터 없음
Lindsay Burns
Senior Vice President of Neuroscience4.3yrs데이터 없음데이터 없음

3.9yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 관리: SAVA 의 관리팀은 경험 ( 3.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Remi Barbier
Founder26.2yrsUS$6.26m2.79%
$ 16.2m
Sanford Robertson
Lead Independent Director25.8yrsUS$546.16k2.37%
$ 13.8m
Patrick Scannon
Independent Director16.6yrsUS$438.42k0.0025%
$ 14.6k
Michael O'Donnell
Independent Director26.1yrsUS$438.42k0.017%
$ 100.1k
Grant Schoenhard
Member of Scientific Advisory Board9.8yrsUS$558.31k데이터 없음
Richard Barry
Independent Director3.1yrsUS$546.16k0.98%
$ 5.7m
Robert Gussin
Independent Director21.3yrsUS$546.16k0.027%
$ 154.6k
Claude Nicaise
Independent Directorless than a yearUS$474.50k0%
$ 0
Robert Anderson
Independent Directorless than a yearUS$474.50k0%
$ 0
Pierre Gravier
Independent Directorless than a yearUS$474.50k0%
$ 0

13.2yrs

평균 재임 기간

68.5yo

평균 연령

경험이 풍부한 이사회: SAVA 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 13.1 년).